Iberdomide

Generic Name: Iberdomide

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇N_₃O_₅

CAS Number: 1323403-33-3

Unique Ingredient Identifier: 8V66F27X44

Background: Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.

Clinical Trials

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Etentamig
Drug: Iberdomide

First Posted Date: 2025-03-26

Last Posted Date: 2025-03-26

Lead Sponsor: TeneoOne Inc.

Target Recruit Count: 135

Registration Number: NCT06896916

Isatuximab and Iberdomide As Immunotherapy for High Risk in Smouldering Myeloma

Phase 2

Not yet recruiting

Conditions: Smouldering Myeloma

Interventions: Drug: Isatuximab
Drug: Iberdomide
Drug: Dexamethasone

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: University College, London

Target Recruit Count: 63

Registration Number: NCT06762769

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent Multiple Myeloma

Interventions: Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Bone Scan
Procedure: Chest Radiography
Procedure: Computed Tomography
Biological: Daratumumab
Drug: Dexamethasone
Biological: Elotuzumab
Drug: Iberdomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2025-01-21

Last Posted Date: 2025-03-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 37

Registration Number: NCT06785415

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1

Recruiting

Conditions: Myeloma
Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Iberdomide
Drug: Dexamethasone

First Posted Date: 2024-07-24

Last Posted Date: 2024-11-20

Lead Sponsor: Omar Nadeem, MD

Target Recruit Count: 49

Registration Number: NCT06518551

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Iberdomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Teclistamab

First Posted Date: 2024-06-18

Last Posted Date: 2025-04-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT06465316

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 1 locations

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Relapsed Multiple Myeloma
Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Biological: Talquetamab
Drug: Iberdomide
Drug: Dexamethasone
Procedure: Bone Marrow Biopsy

First Posted Date: 2024-04-04

Last Posted Date: 2025-05-01

Lead Sponsor: Thomas Martin, MD

Target Recruit Count: 32

Registration Number: NCT06348108

Locations: 🇺🇸
University of Calfornia, San Francisco, San Francisco, California, United States

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Not yet recruiting

Conditions: Recurrent Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Drug: Iberdomide
Biological: Belantamab Mafodotin
Drug: Dexamethasone
Procedure: Echocardiography
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2024-01-30

Last Posted Date: 2025-03-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 88

Registration Number: NCT06232044

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
OhioHealth O'Bleness Hospital, Athens, Ohio, United States
🇺🇸
OhioHealth Marion General Hospital, Marion, Ohio, United States

and more 32 locations

Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Isatuximab
Drug: Dexamethasone

First Posted Date: 2024-01-22

Last Posted Date: 2024-10-18

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 411

Registration Number: NCT06216158

Locations: 🇩🇪
Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪
Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie, Berlin, Germany
🇩🇪
Helios Klinikum Berlin-Buch, Berlin, Germany

and more 50 locations

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Iberdomide

First Posted Date: 2024-01-22

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 87

Registration Number: NCT06215118

Locations: 🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 28 locations

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Iberdomide
Procedure: Patient Monitoring
Procedure: Positron Emission Tomography
Procedure: Skeletal Survey X-Ray

First Posted Date: 2023-12-22

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT06179888

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 56 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy